Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Genflow Biosciences Plc ( (GB:GENF) ) is now available.
Genflow Biosciences has received administrative approval for approximately €4 million in non-dilutive funding support from Belgium’s Wallonia region to advance its lead gene therapy, GF-1002, for the treatment of MASH, with the three-year support package expected to begin disbursement by May 2026 and to cover eligible project expenses incurred from 2025. For 2026, the company is prioritising capital-efficient pipeline development and early-stage collaborations, highlighting upcoming data from its dog ageing study GF-1004, progress in glaucoma delivery optimisation through LNP and CRO partnerships, and continued work on sarcopenia and its ExoFastTrack platform, all aimed at strengthening its ageing-focused gene therapy pipeline and enhancing prospects for future partner engagement and shareholder value.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Spark’s Take on GB:GENF Stock
According to Spark, TipRanks’ AI Analyst, GB:GENF is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.
To see Spark’s full report on GB:GENF stock, click here.
More about Genflow Biosciences Plc
Genflow Biosciences Plc is a European-based biotechnology company headquartered in the UK with R&D facilities in Belgium, focused on pioneering gene therapies for age-related diseases. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene and is being developed for conditions such as Metabolic Dysfunction-Associated Steatohepatitis (MASH), while the company also runs a 12‑month proof-of-concept gene therapy trial in aged dogs and advances additional programmes in sarcopenia and glaucoma.
Average Trading Volume: 1,489,096
Technical Sentiment Signal: Buy
Current Market Cap: £9.62M
See more data about GENF stock on TipRanks’ Stock Analysis page.